Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

The biological diversity of high-risk prostate cancer makes it difficult to find an effective first-line or second-line cancer treatment. Therapy failure is high for men with high-risk localized cancer, having a risk of a biochemical relapse between 42% and 50% following radical prostatectomy and 36-43% after radiation therapy. Moreover, very high-risk prostate cancers with distant metastasis, accounting for 22% of the prostate cancer diagnoses, have a worse prognosis with overall 5-year survival rates of only 30-45%. Personalized treatment plans based on ex vivo therapy testing on patient-derived prostate cancer cultures could offer a more tailored approach by predicting the most effective therapy for each patient's specific tumor profile. Ex vivo patient-derived 3D cultures may be an excellent solution which is able to recapitulate histological characteristics of the original tumor and could be utilized to assess tumorigenesis, potential drug targets and patients' drug responsiveness. Aside from the preservation of histological characteristics of the original tumor, ex vivo patient-derived 3D cultures are able to maintain physiological tumor features by preservation of the tumor micro-environment which is essential for testing selected types of anti-cancer drugs. Ex vivo patient-derived 3D cultures are generated from small fragments of tumor tissue containing organ-specific (tumor) cell types, which are cultivated into miniature, self-organizing prostate tumors using one of two principal techniques: organoid (i.e., utilizing a basement membrane exact) or tumor replica technology (i.e., utilizing a suspension culture without matrix support). Success rates of culturing prostate cancer organoids based on left-over tissue after radical prostatectomy are excellent, varying between 90% and 98%, however, for the more high-risk (metastasized) prostate cancers, the success rates vary considerably from 16% to 44% based on the small amount of needle biopsy tissue and inherent low cellular yield, limited cell-cell interaction, or prostate cancer subtype specific growth factors. To overcome the above-mentioned low success-rates, the high turnaround time, and challenges of deriving (metastasized) prostate cancer organoids, the tumor replica technology may be interesting to explore. The tumor replica technology is optimized by Rianne Vaes at the Maastro Lab in the IPON-3 study for lung cancer (NL79010.068.21) and has increased the success rate from 17% to 70% (unpublished). So far, only one study generated prostate cancer tumor replicas utilizing this technique and showed an excellent success rate of 100% after radical prostatectomy. However, the establishment and use of tumor replicas derived from high-risk (metastatic) prostate cancer biopsies have been described yet, nor have been from prostate cancer recurrence following initial radiation therapy (i.e. radioresistant prostate cancer). Moreover, only one study demonstrated the capability of predicting the therapy response for prostate cancer drugs as well as radiation therapy on patient-derived 3D organoids of treatment-naïve prostate cancer patients utilizing left-over prostatectomy tissue. The number of patients on which treatment responsiveness was tested, however, was low (3 patients tested for prostate cancer drugs and 2 for radiation therapy).